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Highlights 
 
 Female-specific risk factors, among which preeclampsia, may have additional value in 
cardiovascular screening. 
 Non-invasive imaging techniques can be helpful to detect early-stage cardiovascular lesions as a 
sign of subclinical atherosclerotic disease. 
 Preliminary studies show positive effects of short-term lifestyle interventions following 
preeclampsia. 
 There is a need for clinical practice guidelines that provide long-term strategies in women after 
preeclampsia in pregnancy to improve cardiovascular health. 
  
Abstract 
Women who develop preeclampsia have an increased risk of cardiovascular disease (CVD) later in life. 
However, current guidelines on cardiovascular risk assessment and prevention are unclear on how and 
when to screen these women postpartum, and about the role of a positive history of preeclampsia in 
later-life CVD risk management. The aim of this review is to discuss the present knowledge on 
commonly used cardiovascular screening modalities available to women with a history of preeclampsia, 
and to discuss recent developments in early detection of CVD using cardiovascular imaging.  
Furthermore, we explore how female-specific risk factors may have additional value in cardiovascular 
screening, in particular in relatively young women, although their implementation in clinical practice is 
challenged by inconsistent results and lack of long-term outcome data. Non-invasive imaging 
techniques, e.g. coronary artery intima-media thickness (CIMT), can be helpful to detect subclinical 
atherosclerotic disease, and coronary artery calcium scoring (CACS) has shown to be effective in early 
detection of cardiovascular damage. However, whilst more short-term and long-term follow-up studies 
are becoming available, few studies have investigated women with a history of preeclampsia in the 
fourth and fifth decade of life, when early signs of premature CVD are most likely to become apparent. 
Further studies are needed to inform new and improved clinical practice guidelines, and provide long-
term strategies to effectively prevent CVD, specifically targeted at women with a history of 
preeclampsia. Additionally, evaluation of feasibility, cost-effectiveness and implementation of CVD 
screening and prevention initiatives targeted at former preeclampsia patients are needed.  
 
1 Introduction  
 
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality that affects up to 2-
5% of all pregnancies. After delivery, preeclampsia usually resolves within a few days. However, the 
focus of research on preeclampsia is slowly shifting towards its long-term complications. In particular, a 
well-established association exists between preeclampsia and an increased risk of CVD later in life.[1-7] 
However, routine cardiovascular screening in women who have had preeclampsia is hindered by 
conflicting results on the prevalence of CVD risk factors postpartum and uncertainty about optimal 
timing, and the relatively unexplored role of female-specific risk factors. The aim of this review is to 
discuss the present knowledge, opportunities for and concerns of cardiovascular screening in women 
with a history of preeclampsia, in particular in view of new developments in risk factor assessment and 
cardiovascular imaging.  
 
1.2 Preeclampsia: prevalence and definitions 
Preeclampsia is defined as a syndrome consisting of gestational hypertension (systolic blood pressure ≥ 
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg after 20 weeks of gestation) coinciding with one 
or more of the following new-onset conditions: de novo proteinuria, maternal organ dysfunction or 
placental dysfunction.[8] About 3-5% of pregnancies are affected, and besides peripartum hemorrhage, 
preeclampsia is the second most important direct cause of maternal mortality worldwide.[9, 10]  
 
1.3 Preeclampsia as an early indicator of cardiovascular risk 
For most women affected by preeclampsia, including those cases with severe early-onset disease, 
clinical features resolve within days after delivery of the baby and placenta. In spite of the short-term 
clinical recovery, recent evidence consistently shows that long-term cardiovascular health in former 
preeclamptic patients is compromised. [1-7] Original cohort studies that have investigated the incidence 
of CVD events after preeclampsia are listed in Table 1. Outcomes of these studies have now been the 
subject of a number of excellent systematic reviews and meta-analyses. In summary, women who have 
been diagnosed with preeclampsia in any of their pregnancies have an approximated twofold risk of 
developing major CVD events (i.e. myocardial infarction and stroke) and an almost fourfold increased 
risk of developing hypertension compared with women who do not develop preeclampsia. It appears 
that CVD events following preeclampsia generally occur at a much younger age than in other women 
within the same population.[1, 4, 5, 11] In a recent study by our group, we estimated the onset of 
hypertension, type 2 diabetes mellitus, myocardial infarction and stroke after preeclampsia to be on 
average 8-10 years earlier than in women with normal pregnancy outcomes.[12] The risk of CVD events 
is more pronounced in the subgroup of women with so-called early-onset preeclampsia (generally 
defined as preeclampsia occurring before 34 weeks of gestation).[4, 13] In these women, there is a 7- to 
8-fold increased incidence of ischemic heart disease, cerebrovascular disease, and peripheral arterial 
disease later in life.[1, 6] The mechanisms underlying this increase in life-time cardiovascular risk are 
complex and much debated. Preeclampsia and atherosclerosis are likely to share common pathological 
features, including similar contributing risk factors (e.g. hypertension, obesity, inflammation), 
characteristic alterations of the vessel wall (intimal thickening, fat accumulation in middle to large 
arteries) and endothelial cell dysfunction.[14] One could argue that pregnancy serves as a “stress test” 
for cardiovascular health, and that preeclampsia is associated with temporary vascular compromise, 
which subsides after pregnancy but reappears with ageing as CVD later in life (see Figure 1). Following 
this hypothesis, preeclampsia may therefore be considered as a “red flag” and offer opportunities for 
early-life identification of high risk individuals, susceptible to premature atherosclerosis and CVD events, 
and serve as a potent risk marker to select a target population eligible for intervention trials at a young 
age to prevent further development of CVD. However, given the complexity and interaction of risk 
factors leading up to long-term increased CVD risk, as well as limited data on development of CVD risk 
over time (in particular in the fourth and fifth decade of life), the question arises how this information 
can best be used to design cardiovascular risk screening and prevention programs.  
 
2 Screening for subclinical cardiovascular disease after preeclampsia 
 
2.1 Estimation of global cardiovascular risk 
Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) recommend 
cardiovascular risk assessment in men and women from the age of 40 years onwards. Although the two 
guidelines agree on this recommendation, their proposed risk estimation algorithms differ: AHA 
promotes the use of the race- and sex-specific Pooled Cohort Equations, whereas ESC recommends the 
use of the Systematic Coronary Risk Evaluation Project (SCORE).[15, 16] These risk assessment tools 
overlap, apart from the parameters: race, high-density lipoprotein (HDL) cholesterol, stratification for 
the use of blood pressure lowering medication, which are only used in the Pooled Cohort Equations. 
Most CVD risk factor screening programs are based on these well-established algorithms, although there 
is growing evidence for sex-specific differences in risk factor prevalence and in their contribution to 
development of CVD.[17, 18] In their latest recommendations, both U.S. and European guidelines now 
do include statements on cardiovascular risk assessment in women with a history of preeclampsia. The 
2011 AHA guideline on prevention of CVD in women recommends to obtain a detailed obstetric history 
when a woman presents for the first time, and recommends to monitor and control CVD risk factors in 
women after a pregnancy complicated by preeclampsia.[19] However, no recommendations are made 
with respect to the questions of when to start screening, what targets to use, and what potential value a 
positive history of preeclampsia may have in improving risk classification.[15, 15, 16, 19] Similar, the 
2014 AHA guideline on stroke also points towards the role of preeclampsia as a potential identifier of 
stroke risk. However, the practical recommendations are no different from the AHA guideline for CVD 
prevention in women.[20] More recently, in a multidisciplinary guideline from the Netherlands focused 
on cardiovascular risk management after reproductive disorders current evidence for the association 
between reproductive disorders – amongst which PE – and the development of CVD has been updated 
and evaluated.[21] The authors advise on specific screening after preeclampsia based on current global 
CVD risk assessment protocols and blood pressure measurement at regular intervals postpartum, but 
note a lack of strong evidence and absence of longitudinal studies addressing the development of 
cardiovascular risk over time.  
 
2.2 Major and contributing CVD risk factors  
Current evidence suggests that women with a history of preeclampsia show a high prevalence of major 
traditional CVD risk factors, as well as other contributing factors and non-traditional risk factors.[22-27] 
An overview of studies on established and novel CVD risk factors in women with a history of 
preeclampsia, including anthropometric measures, circulating markers and imaging modalities, is 
presented in Table 2. In a recent meta-analysis by Hermes et al. several traditional risk factors for CVD 
(glucose, insulin, triglycerides, total cholesterol, HDL-cholesterol, low-density lipoprotein (LDL) 
cholesterol and homocysteine levels) were confirmed to be associated with previous preeclampsia in 
comparison to same-age women with a history of an uncomplicated pregnancy.[28] Moreover, in a 
recent study, we found that it is not uncommon to find the presence of a combination of multiple 
independent major CVD risk among women with a history of early-onset preeclampsia within the first 
few years postpartum, with over half of women exhibiting 2 or more major risk factors and up to 20% of 
women with 3 or more major risk factors.[22] Despite these high prevalences, however, the estimated 
10-year absolute risk of a cardiovascular event calculated by the Framingham Risk Score (FRS) was low 
for virtually all women.[22] This is explained by their relative young age, as these women are still 
premenopausal and CVD event rates are low. It can be speculated that assessment of CVD risk based on 
FRS 10-year predictions is likely to substantially underestimate the actual risk and estimations of life-
time risk may be more appropriate for these women.[29-32] In general, there is increasing support for 
the concept of using lifetime risk rather than the 10-year CVD risk, or the relative risk scores, in CVD 
screening programs, comparing individual CVD risk with the “ideal risk” of age-matched controls, to 
facilitate early identification of women at an increased risk of premature CVD. In addition, studies using 
surrogate endpoints of CVD, e.g. elevated carotid intima-media thickness (cIMT) and coronary artery 
calcium scoring (CACS), show more progression of subclinical atherosclerosis in women with a high 
lifetime cardiovascular disease risk compared with women with a low lifetime cardiovascular disease 
risk.[33, 34] Indeed, the recent update of the SCORE algorithm includes a specific relative risk chart for 
women to estimate lifetime risk, which can be helpful for clinicians.[30] In summary, in spite of 
increased attention for long-term follow-up after preeclampsia, effective and timely identification of 
women at risk of CVD remains a challenge. Tracking of CVD risk factor profiles after preeclampsia from 
the initial screening in the first years postpartum into the later stages of life is needed, and novel risk 
models that incorporate preeclampsia as a risk factor for CVD need to be developed. 
 
2.3 Non-traditional markers of CVD risk  
Because preeclampsia and CVD share common pathophysiological pathways, biomarkers used in 
prediction of preeclampsia might be useful in predicting CVD later in life. Novel cardiovascular 
biomarkers include markers associated with endothelial dysfunction and inflammation (intercellular 
adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), C-reactive protein (CRP), 
interleukin-6 (IL-6), interleukin-10 (IL-10), E-selectin), thrombosis (homocysteine, von Willibrand factor 
(VWF), fibrinogen, fibronectin, D-dimer, plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen 
activator (tPA)), vasoconstriction (endothelin) and angiogenesis (vascular endothelial growth factor 
(VEGF), soluble Fms-like tyrosine kinase-1 (sFLT-1) and tumor necrosis factor alpha (TNF-a)).[35] Several 
of these markers have been shown to be elevated up to 20 years after pregnancy and may be involved 
in the pathogenesis of both preeclampsia and atherosclerosis, although the data are somewhat 
conflicting and heterogeneous.[24, 36] In a recent meta-analysis on biomarker levels in women with a 
history of preeclampsia, for most of these novel biomarkers a trend towards higher levels was found in 
women with a history of a hypertensive pregnancy compared with controls with normotensive 
pregnancies, although only homocysteine levels were shown to be significantly higher.[35] Despite initial 
promising observations in prospective cohort studies, the implementation of novel biological markers in 
addition to the repertoire of traditional cardiovascular risk factors is still much debated and is not 
routinely recommended in clinical practice.[34, 37] It appears that for women, the contribution of novel 
markers to CVD risk stratification may be more promising than for men, as demonstrated by e.g. the 
recently developed Reynolds Risk Score for women that incorporates baseline CRP levels into the 
estimated CVD risk algorithm.[38] In a short-term follow-up study that included mostly term and mild 
cases of hypertensive disease in pregnancy tested 2.5 years postpartum, the Reynolds Risk Score and 
the more traditional risk algorithms (SCORE and Framingham Risk Scores), we more or less equivalent in 
estimating predicted 10-year CVD risk.[39] It will be interesting the see whether or not these risk 
algorithms perform differently in cohorts with longer-term (>10 years) postpartum follow-up, and 
whether or not novel risk markers (in particular inflammatory markers) may prove to be beneficial in 
improving CVD risk prediction in models specifically designed to predict CVD in women with previous 
preeclampsia.  
 
2.4 Cardiovascular imaging 
Recent advances in noninvasive cardiovascular imaging have enabled early detection of signs of 
subclinical atherosclerosis and indirect measures of arterial compliance.[40-42] This may be helpful as 
surrogate endpoints for intervention studies, as well as potentially add to global CVD risk assessment 
and guide treatment decisions.[43-47] Subclinical atherosclerosis is commonly assessed by carotid 
intima-media thickness (cIMT), coronary artery calcium score (CACS), coronary computed tomography 
angiography (CCTA) and cardiac magnetic resonance imaging (CMR).[5, 46-58] In recent years, some 
groups have started to evaluate these imaging techniques in former preeclampsia patients, as discussed 
below. 
 
2.4.1 Carotid intima-media thickness  
CIMT is associated with the development of atherosclerosis and serves as an early indicator of CVD 
risk.[59-63] In a recent study in adults aged under the age of 45 years variation in cIMT was shown to be 
an early independent marker of later-life first-time myocardial infarction or stroke, although with 
modest discriminative power (hazard ratio (HR) 1.40 per standard deviation (SD) increase in cIMT, 95% 
confidence interval (CI) 1.11 – 1.76).[64] Since preeclampsia appears to be associated with premature 
atherosclerosis, cIMT may be of particular interest for early detection of vascular abnormalities in these 
women. Current studies exploring cIMT in women with previous preeclampsia have shown mixed 
results. In most studies, cIMT is increased in women after an episode of a hypertensive pregnancy [5, 49-
51, 53, 55], although numbers are small and one study could not confirm these findings.[54] 
Furthermore, the added value of including cIMT in the current risk profiles in the general population is 
uncertain and it is not likely to improve risk classification.[15, 65] Given the limited data available, it is 
unknown to what extend cIMT contributes to risk classification in formerly preeclamptic women. 
 
2.4.2 Coronary artery calcium score 
Coronary artery calcium score (CACS) is a non-invasive measurement of subclinical coronary 
atherosclerosis using low-dose (1 milliSievert) computed tomography (CT) scanning of the coronary 
arteries without administration of an intravenous contrast medium. CACS is a strong and independent 
predictor of cardiovascular events.[66, 67] The additional value of CACS for CVD risk classification has 
mostly been demonstrated in asymptomatic persons with an intermediate risk of CVD, i.e. an estimated 
10-year event risk of 5%-20% based on traditional cardiovascular screening.[46, 48, 68-73] Two 
retrospective cohort studies have evaluated CACS in women with a history of hypertensive pregnancy 
disorders, and both found a positive association between CACS and self-reported hypertension in 
pregnancy.[74, 75] There are no published prospective studies yet to evaluate CACS in previous 
preeclamptic patients. Although CACS is a non-invasive measurement, holds great promise as a CVD risk 
marker, and provides the most direct evidence for cardiovascular damage, radiation dose and costs 
should be taken into account when considering CACS for risk assessment. The value of CACS will 
probably only be evident in individuals above the age of 45 years, as calcification of atheromatous 
plaques occurs relatively late in the development of atherosclerosis. More recently, evaluation of early-
stage coronary artery atherosclerotic lesions by coronary computed tomography angiography (CCTA) 
has been suggested. This technique may have the advantage over CACS of being able to identify non-
calcified plaques, and estimate the total atherosclerotic burden of the coronary artery tree.[76-78] In a 
number of retrospective cohort studies, it was shown that with CCTA, even in persons with very low 
CACS, a substantial presence of non-calcified plaques (or “plaque burden”) can be found.[76, 79, 80] 
However, CCTA requires a higher radiation dose (3-4 milliSievert) and the use of intravenous contrast. 
To our knowledge, studies evaluating CCTA in women with a history of PE have not been conducted so 
far. Radiation dose, use of intravenous contrast material, and extra costs may limit the use of CCTA in 
younger age groups. In summary, there is growing interest in CACS and possibly low dose CCTA for CVD 
risk assessment in the general population.[44] CACS seems to be the most promising imaging marker 
and the AHA guideline now recommends considering CACS if the treatment decision is inconclusive 
based on global CVD risk assessment.[15]  
2.4.3 Cardiac magnetic resonance imaging  
Cardiac magnetic resonance (CMR) is a non-invasive imaging technique that enables detailed soft tissue 
characterization and can assess different parameters of cardiovascular function, as well as 
macrovascular and microvascular features of CVD without using ionizing radiation.[45, 81] In addition, 
enhancement of CMR with adenosine perfusion MRI (also called ‘adenosine stress MRI’) can be used to 
identify both ischemic coronary artery disease as well as non-obstructive coronary disease in 
symptomatic women without major plaques.[82] It is unclear whether or not there is a role for 
adenosine stress MRI in the detection of cardiac dysfunction in asymptomatic women. However, CMR 
can be used to identify macroscopic fibrosis with late gadolinium enhancement, and evaluate early 
(preclinical) myocardial fibrosis with so-called T1 mapping.[83, 84] In addition, CMR may be used as an 
alternative technique to evaluate aortic stiffness, which is strongly related to systolic hypertension and 
is associated with future cardiovascular events.[85, 86] Although sensitivity of CMR is high, the 
specificity is moderate for detecting major coronary artery lesions, and the availability and costs of CMR 
equipment currently limit large-scale use.[45] Another problem is the uncertainty of translating 
abnormal CMR findings observed at a young age to actual later-life CVD event risks, as longitudinal 
studies with sufficient follow-up time are not available. The use of CMR for screening purposes in 
asymptomatic, high-risk populations, such as women with a history of preeclampsia, needs to be further 
explored to establish a more conclusive role for CMR in the screening of CVD risk after preeclampsia.  
 
3 Opportunities for prevention 
 
Guidelines for CVD risk management increasingly include recommendations for cardiovascular 
prevention in women with a history of preeclampsia. However, and as demonstrated in this review, 
optimal screening and prevention in this high-risk group of young – apparently healthy – women still 
needs to be evaluated further.[16, 19, 21] In current practice, women who experienced preeclampsia 
are considered as “cured” after delivery and referred back to primary care without a plan for 
cardiovascular follow-up or prevention.[87] Question arises as to whether these women should be 
offered specific prevention strategies. Important to the debate on screening in this population is the 
observation that estimated 10-year CVD risks is low in this young age group despite multiple modifiable 
risk factors being present shortly postpartum. It seems rational to implement CVD screening and 
prevention on the basis of the expected high ‘lifetime’ risk of CVD in these women. However, 
uncertainties exist about the development and contribution of risk factors over time, and further efforts 
are needed to evaluate progression of early-life risk exposures with ageing, in particular after the first 10 
years postpartum (or roughly from the age of 40 years onwards), when actual signs of CVD are expected 
to occur. Another question arises as how to organize effective screening and intervention programs in 
these women. Currently, a few clinics have initiated postpartum CVD risk assessment and counseling for 
women with who experience (mostly severe) preeclampsia at six to twelve months postpartum, offering 
global CVD risk assessment and an advice on lifestyle modifications.[88] A recent report from Cusimano 
et al. (2014) describing the experiences of a recently set-up maternal health clinic for CVD risk 
assessment after pregnancy complications (including gestational hypertension and preeclampsia), 
suggests that women are highly motivated to optimize lifestyle in the postpartum period, although only 
40% of the booked patients showed up at the initial appointment.[89-91] It may be useful to consider 
targeted clinics that incorporate self-management (and eHealth) applications to improve adherence to 
postpartum prevention programs in women with reproductive disorders. A multidisciplinary approach, 
frequent interactions, and a more integrated women’s health approach to simultaneously target young 
women with reproductive disorders associated with increased CVD risk, e.g. women with polycystic 
ovary syndrome (PCOS), preeclampsia and premature ovarian failure, can be considered.[92][93]  
 
4 Summary and conclusions 
 
In spite of a call for increased attention for long-term CVD risks after preeclampsia, translating this 
knowledge to clinical practice and population health initiatives remains a challenge. In this review, we 
set out to provide an overview of current data on CVD risk screening after preeclampsia and have aimed 
to discuss new and promising screening modalities and important caveats in CVD risk stratification and 
implementation. Importantly, in our view, identification of women with high risk, i.e. those women who 
will benefit most from early screening and prevention measures, remains the key to successful 
postpartum intervention studies. Routine use of biomarkers and modern CVD imaging techniques holds 
promise in research settings, but needs to be further evaluated before being implemented in clinical 
practice. Improved lifestyle interventions programs, developed for the general population, in particular 
those making use of smart technologies, merit further investigation. Continuing awareness of the high 
risk of premature CVD after preeclampsia should be raised among patients, specialists, and general 
practitioners to promote healthy cardiovascular lifestyles and ensure timely detection of CVD. 
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Table 1: overview of original cohort studies assessing CVD after preeclampsia 
 
First author, 
year 
Total study-
population 
Cases Controls  Primary outcome Follow up 
Bhattacharya, 
2011 
34854 PE (n=2026), PIH 
(n=8891) 
Normal blood 
pressure  
(n=23937) 
CV event, IHD, stroke, hypertension 
(all fatal/non-fatal) 
26 – 48 years  
Callaway, 2011 2112 Hypertensive 
disorder of 
pregnancy  (HDP, 
n=191) 
No HDP (n=1921) Hypertension 21 years (age at FU 46.41 
years, SD 4.97 years) 
Callaway, 2007 3639 HDP (n=333) No HDP (n=3306) DM, self-reported anthropometrics 21 years 
Carr, 2009 31463 PE (n=2032) No PE (n=29431) DM Median 8.2 years (IQ-
range 4.8; 13.2 years) 
Cassidy, 2009 498 HDP (n=52) No HDP (n=446) CAC score, CVD risk factors 
(hypertension, dyslipidemia), self-
reported DM2, CHD, stroke 
Mean 27 years 
Engeland, 2011 226832 PE (n=8832) No PE (n=215988) Diabetes Mellitus Mean 3.7 years (0-6 
years) 
Freibert 2011 3909 HDP (n=222) 
Preterm birth 
(n=324) 
Pregnancy without 
complications 
(2558) 
Self-reported non-fatal MI, AP, heart 
failure, arrhythmia 
Unknown (age ≥ 50 
years) 
Funai, 2005 37061 PE (n=1070) No PE (n=35991) Fatal CV event Median 30 years (24.5 – 
36.5 years) 
Garovic, 2010 4782 HDP (n=643) Normotensive 
pregnancy (n=3421) 
Fatal/non-fatal IHD, Non-fatal stroke, 
DM (all self-reported); hypertension, 
dyslipidemia 
Unknown (median age ≥ 
38 years) 
Hannaford, 
1997 
214356 Toxemia (n=3000) No toxemia 
(n=18451) 
IHD & stroke (fatal/ non-fatal), 
hypertension  
Unknown 
Haukkamaa, 
2009 
767 PE (n=35), PIH 
(n=61) 
Healthy parous 
(n=489) and 
nulliparous (n=182) 
controls 
Non-fatal IHD, hypertension 
IMT, lipids, DM2 
Unknown (≥ 30 years, 
mean age 55-57 years)) 
Henriques, 
2014 
60 PIH (n=30) Uncomplicated 
pregnancy (n=30) 
FMD 
anthropometric variables, metabolic 
Mean 15.2 years (10 – 20 
years, SD 3.5 years) 
variables 
      
Irgens, 2001 626272 PE term (21506), 
PE preterm 
(2649) 
No PE, term 
(n=576099) 
IHD & stroke (fatal) 0 – 25 years 
Jonsdottir, 
1995 
7543 HDP (n=374) General population 
(n=7169) 
Fatal IHD 0 – 59 years 
Kaaja, 2005 3559 PE (n=397) No PE (n=3162) DM2, dyslipidemia, hypertension, 
heart failure, AP 
28 years 
Kestenbaum, 
2003 
124141 PIH (n=10687), 
mild PE 
(n=15508), severe 
PE (n=5044) 
Normotensive 
pregnancy 
(n=92902) 
Fatal/non-fatal CV event Mean 7.8 years (IQ-
range 4.8; 7.6; 10.6 
years) 
Libby, 2006 7178 PE (n=810) No PE (n=6377) DM2 Unknown (median age 
71 years, IQ-range 67; 
75/76 years) 
Lin, 2011 1132064 PE/eclampsia No PE/eclampsia Fatal/non-fatal CV event & MI, IHD 1 – 6 years 
Lykke, 2010 782287 PIH (n=7449), 
Mild PE (26810), 
Severe PE 
(n=7016) 
No hypertensive 
disorder 
(n=741012) 
CV event (fatal), IHD & stroke (fatal/ 
non-fatal) hypertension, DM 
Median 14.8 years (0.25 
– 30.2 years) 
Magnussen, 
2009 
15065 HDP (n=1433) No HDP (n=13632) Hypertension, DM2, dyslipidemia Mean 16.3 – 16.6 years 
(SD 8.2 years) 
Mongraw, 2010 14403 PE (n=481) No PE (n=13922) Fatal CV event Median 37 years 
Ray, 2005 1026265 PE (n=36982), PIH 
(n=20942) 
No maternal 
placental syndrome 
(n=950885) 
Fatal/non-fatal CV event Median 8.7 years 
Shalom, 2013 22814 HDP (n=2072) No HDP (n=20742) Hypertension 
Any relevant hospitalization 
10-12 years 
Skjaerven, 2012 836147 All PE (n=34824) 
- Term PE 
(n=26708) 
- Preterm PE 
(n=5886) 
All no PE 
(n=801323) 
Term no PE 
(n=712181) 
Fatal CV event 7 – 42 years 
Smith, 2001 129920 PE (n=22781) No PE (n=107139) Fatal/non-fatal IHD 15 – 19 years 
Wang, 2011 5807 HDP (n=1092) No HDP (4715) Fatal/non-fatal stroke Mean 6.64-6.4 (SD 1.57 
years) 
Wikstrom, 2005 403550 Hypertensive 
disease (n=20469) 
- PIH (n=9718) 
- mild PE 
(n=9718) 
- severe PE 
(n=2815) 
Uncomplicated 
pregnancy 
(n=347870) 
Fatal/non-fatal IHD 14 years (?) 
Wilson, 2003 2790 PIH (n=951) 
PE (n=1043) 
No HDP (n=796) Fatal/non-fatal IHD, stroke, 
hypertension, VTE and kidney 
disease 
10 – 48 years 
Wu, 2014 944474 HDP (n=13633) 
- PIH (n=2361) 
- chron 
hypertension 
(n=731) 
- PE (n=8609) 
- superimposed 
PE (n=594) 
No HDP (n=13633) ESRD, DM2 Median 9 years (IQ-
range 7.09-10.02 years) 
 
 
 
LPE = preeclampsia, PIH = pregnancy induced hypertension, HDP = hypertensive disorders of pregnancy, PCOS = polycystic ovary syndrome, POI = 
primary ovarian insufficiency, CV = cardiovascular, CVD = cardiovascular disease, IHD = ischemic heart disease, CHD = coronary heart disease, MI 
= myocardial infarction, AP = angina pectoris, IMT = intima media thickness, FMD = flow-mediated dilatation, ESRD = end-stage renal disease, 
CAC score = coronary artery calcium score, VTE = venous thromboembolism, IQ = inter quartile, SD = standard deviation 
egend: 
 
 
Table 2: items used in cardiovascular screening  
 
 
Level or occurrence of items compared to healthy women 
 
Screening method Short term  
(< 5 years) 
Long term  
(> 5 years) 
Items commonly used in CVD risk assessment 
 Gender n.a.  n.a. 
 Age n.a. n.a. 
 Race Unchanged[1] Unknown[2] 
 Total cholesterol Increased in most studies[1, 3-5] Unchanged or marginally  
increased in most studies[3, 6-13] 
 HDL cholesterol Decreased in most studies[1, 3-5] Unchanged or marginally decreased in most 
studies[3, 6-14] 
 Systolic BP Increased in most studies[1, 3-5][15-
17] 
Increased in most studies[2, 3, 6-13, 18] 
 BP medication Increased[15] Increased[3, 6-13] 
 Diabetes Unchanged[1] Unchanged[2] 
 Smoking Unchanged[6][15] Inconclusive (unchanged or  decreased)[4, 17] 
 Metabolic syndrome Increased[2, 3, 6-13] Increased[1] 
 Family history of CVD Unchanged[6] Increased in most studies[4, 15] 
 BMI Increased in most studies[3, 6-13] Inconclusive (unchanged or  increased)[1, 4, 5, 15, 
17] 
 Triglycerides Unchanged in most studies[2, 3, 6-
13] 
Unchanged or marginally  
increased[1, 4, 5] 
 Glucose Increased in most studies[2, 3, 6-14] Inconclusive (unchanged or  increased)[1, 3-5] 
 HbA1c Unknown Inconclusive (unchanged or  increased)[2, 3, 6-13] 
 
Non-classic biomarkers 
 CRP Inconclusive (unchanged or 
increased)[3, 6, 12] 
Inconclusive (unchanged or  increased)[3, 5] 
 Fibrinogen  Unchanged[2, 3, 6-11, 11-14] 
 ICAM ** Unchanged[6] Unchanged[19] 
 VCAM ** Unchanged[19] Inconclusive (unchanged or  increased)[19] 
 Homocysteine ** Increased[12, 19] Increased[4, 19] 
 VWF ** Inconclusive (unchanged or  
increased)[19] 
Inconclusive (unchanged or  increased)[19] 
 Fibrinogen ** Inconclusive (unchanged or  
increased)[19] 
Inconclusive (unchanged or  increased)[19] 
Imaging modalities 
 IMT Increased[12, 19] Inconclusive (unchanged or  increased)[4, 5] 
 FMD Decreased[8-10, 12, 20, 21] Unchanged[5] 
 CACS Not performed Increased[12] 
 cCTA Not performed Not performed 
 CMR Not performed Not performed 
Other modalities 
 ECG  Inconclusive (unchanged or  increased)[13, 22] 
 
 
 
* controls nulliparous healthy controls; ** used in meta-analysis 
 
 
 
LHDL-cholesterol = high-density lipoprotein cholesterol, BP = blood pressure, CVD = cardiovascular disease, BMI = body-mass index, HbA1c = 
hemoglobin A1c, CRP = c-reactive protein, ICAM = intercellular adhesion molecule, VCAM = vascular cell adhesion molecule, VWF = von Willibrand 
factor, IMT = intima-media thickness, FMD = flow-mediated dilatation, CACS = coronary artery calcium score, CCTA = coronary computed 
tomography angiography, CMR = cardiac resonance imaging, ECG = electrocardiography 
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